Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with entering into agreements regarding a loan facility of up to EUR 40 million from the EIB
Mandate

Vinge has advised Oncopeptides in connection with entering into agreements regarding a loan facility of up to EUR 40 million from the EIB

October 16, 2020 Banking and Finance Capital Markets and Public M&A

The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EUR 40 million. The loan may be used to further support the clinical development of melflufen and the company’s transition from a R&D company into a fully integrated global biopharmaceutical company. In connection with the loan agreement, Oncopeptides has entered into a warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Louise Brorsson Salomon, Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Viktor Lennartsson.

 

Related

Vinge has advised Arkivia in connection with a SEK 40 million fundraising

 Vinge has advised the legal tech company Arkivia in connection with a fully subscribed share issue of SEK 40 million with new and existing shareholders. The round was led by node.vc. In connection with the share issue, Arkivia also entered into the Swedish Bar Association’s first framework agreement for a case management system.
October 05, 2026

Vinge has advised Main Capital and Pointsharp in connection with the acquisition of Meaplus AB and Nubibus Software AB

 Vinge has advised Main Capital and its portfolio company Pointsharp in connection with Pointsharp's acquisition of Meaplus AB and Nubibus Software AB. Pointsharp is a Swedish provider of identity and access management solutions as well as secure information exchange, with operations in the Nordics, DACH and Benelux. The acquisition complements Pointsharp's existing offering with capabilities in secure digital communication and strengthens the company's position in the Swedish public-sector market, particularly in the municipal and healthcare segments. The transaction is Pointsharp's sixth add-on acquisition since Main Capital became an investment partner in November 2020.
October 01, 2026

Vinge has advised Main Capital Partners on the acquisition of Confirma Software

 Confirma Software (“Confirma”) is a Nordic vertical software group providing mission-critical B2B software to SMEs in Sweden, Finland, Norway and Denmark. The company operates across five complementary software areas: ERP, Payment Solutions, Financial Solutions, Quality Management Systems and Business Process Solutions. Confirma was founded in 2019 and is headquartered in Stockholm. Supported by approximately 540 professionals, the company serves more than 25,000 customers, including over 500 municipalities, across the Nordics. By combining deep local domain expertise with software embedded in customers’ day-to-day operations, Confirma has developed long-standing customer relationships and a highly recurring revenue profile.
September 25, 2026